Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Neuromuscular Blocking Agent

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43893   clinical trials with a EudraCT protocol, of which   7300   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12 result(s) found for: Neuromuscular Blocking Agent. Displaying page 1 of 1.
    EudraCT Number: 2017-000692-92 Sponsor Protocol Number: MK-8616-089 Start Date*: 2019-02-01
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade ...
    Medical condition: Reversal of neuromuscular blockade (NMB)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10018061 General anesthesia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed) ES (Completed) FI (Completed) BE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-000693-11 Sponsor Protocol Number: MK-8616-169 Start Date*: 2019-08-05
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 4 Double-blinded, Randomized, Active Comparator-controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade ...
    Medical condition: Neuromuscular Blockade reversal
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10057286 Neuromuscular blockade reversal PT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) DK (Completed) FI (Completed) HU (Completed) NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-001926-25 Sponsor Protocol Number: B300201316844 Start Date*: 2013-09-23
    Sponsor Name:Universitair Ziekenhuis Antwerpen
    Full Title: Sugammadex and the diaphragm: recovery of diaphragmatic function and neuromuscular blockade
    Medical condition: Residual neuromuscular blockade and diphragm fatigue
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002078-30 Sponsor Protocol Number: REDNES06052013 Start Date*: 2013-08-08
    Sponsor Name:Onze-Lieve-Vrouw Ziekenhuis
    Full Title: Acceleromyography and diaphragm electromyographic activity during neostigmine or sugammadex enhanced recovery from moderate residual neuromuscular blockade after rocuronium 0.6 mg kg-1: a double bl...
    Medical condition: We will compare usual care (neostigmine) with sugammadex for reversal of a moderate rocuronium-induced neuromuscular blockade and assess the effect on diaphragmatic EMG activity of sugammadex versu...
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000188-33 Sponsor Protocol Number: MK-8616-146 Start Date*: 2017-10-27
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 4 Randomized, Active-Comparator Controlled Trial to Study the Efficacy and Safety of Sugammadex (MK-8616) for the Reversal of Neuromuscular Blockade Induced by Either Rocuronium Bromide or ...
    Medical condition: Reversal of neuromuscular blockade
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10018061 General anesthesia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) BE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-017921-20 Sponsor Protocol Number: none Start Date*: 2010-09-16
    Sponsor Name:Univ. Klinik für Anästhesiologie
    Full Title: Influence of Gender on the Plasma-Effect site equilibration time of propofol anesthetic and Cisatracurium Besylate neuromuscular blocking agent. A pilot study.
    Medical condition: effect of Gender on Pharmacokinetics of Propofol and cisatracurium
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000187-15 Sponsor Protocol Number: MK-8616-145 Start Date*: 2017-09-18
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 4 Randomized, Active-Comparator Controlled Clinical Trial to Study the Safety of Sugammadex (MK-8616) for the Reversal of Neuromuscular Blockade Induced by Either Rocuronium Bromide or Vecu...
    Medical condition: Reversal of neuromuscular blockade
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10018061 General anesthesia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-010840-33 Sponsor Protocol Number: 09005RM-CSRVH Start Date*: 2009-08-17
    Sponsor Name:BELFAST HEALTH & SOCIAL CARE TRUST
    Full Title: Time to resumption of spontaneous respiration in patients administered either suxamethonium or rocuronium followed by sugammadex
    Medical condition: Assessment of time to return of spontaneous ventilation after administration of either suxamethonium or rocuronium followed by sugammadex in patients undergoing planned surgery.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-005792-16 Sponsor Protocol Number: Rocuronium_HVR_OSAS Start Date*: 2012-02-10
    Sponsor Name:Karolinska University Hospital
    Full Title: Effect of reduced cholinergic transmission by rocuronium on the hypoxic ventilatory response in patients with obstructive sleep apnea - before and after three months of continous positive airway pr...
    Medical condition: Obstuctive sleep apnea and acute hypoxic ventilatory response
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10055577 Obstructive sleep apnea syndrome LLT
    Population Age: Adults Gender: Male
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004728-11 Sponsor Protocol Number: MR/EUM202 Start Date*: 2005-03-25
    Sponsor Name:Avera Pharmaceuticals Inc.
    Full Title: A Multicenter, Randomized, Controlled, Observer-Blinded, Dose-Response Study to Evaluate The Efficacy in Tracheal Intubation and Safety of Gantacurium Chloride for Injection in Healthy Adult Patien...
    Medical condition: Adjunct to anesthesia to facilitate tracheal intubation (non-depolarizing neuromuscular blocking agent)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004121-25 Sponsor Protocol Number: NMBA_ELDERLY2019ROCU_REMI Start Date*: 2019-12-17
    Sponsor Name:Rigshospitalet
    Full Title: A single-blinded multicenter randomized study comparing intubating conditions after either rocuronium 0.6 mg/kg or remifentanil 2 µg/kg in elderly patients.
    Medical condition: The aim of this study is to determine the effect on intubating conditions and laryngeal morbidity after either rocuronium 0.6 mg/kg or remifentanil 2 µg/kg in patients with age ≥ 80 years.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10002323 Anesthesia general LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-004343-76 Sponsor Protocol Number: NMBA_ELDERLY2019ROCU_DOSES Start Date*: 2020-02-27
    Sponsor Name:Rigshospitalet
    Full Title: A single-blinded multicenter randomized interventional study of rocuronium 0.3 mg/kg, and 0.9 mg/kg comparing onset time, duration of action and effect on intubating conditions in elderly patients ...
    Medical condition: The aim of this study is to determine the onset time, duration of action and effect on intubating conditions after rocuronium 0.3 mg/kg and 0.9 mg/kg in patients with age ≥ 80 years.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10002321 Anesthesia LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 30 04:55:05 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA